JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M501558200 on April 12, 2005

J. Biol. Chem., Vol. 280, Issue 23, 21791-21796, June 10, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/23/21791    most recent
M501558200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bergseng, E.
Right arrow Articles by Sollid, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bergseng, E.
Right arrow Articles by Sollid, L. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Main Chain Hydrogen Bond Interactions in the Binding of Proline-rich Gluten Peptides to the Celiac Disease-associated HLA-DQ2 Molecule*

Elin Bergseng{ddagger}§, Jiang Xia¶, Chu-Young Kim¶||, Chaitan Khosla¶||**, and Ludvig M. Sollid{ddagger}

From the {ddagger}Institute of Immunology, University of Oslo, Rikshospitalet University Hospital, N-0027 Oslo, Norway and Departments of Chemistry, ||Chemical Engineering, and **Biochemistry, Stanford University, Stanford, California 94305-5080

Received for publication, February 10, 2005 , and in revised form, April 12, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Binding of peptide epitopes to major histocompatibility complex proteins involves multiple hydrogen bond interactions between the peptide main chain and major histocompatibility complex residues. The crystal structure of HLA-DQ2 complexed with the {alpha}I-gliadin epitope (LQPFPQPELPY) revealed four hydrogen bonds between DQ2 and peptide main chain amides. This is remarkable, given that four of the nine core residues in this peptide are proline residues that cannot engage in amide hydrogen bonding. Preserving main chain hydrogen bond interactions despite the presence of multiple proline residues in gluten peptides is a key element for the HLA-DQ2 association of celiac disease. We have investigated the relative contribution of each main chain hydrogen bond interaction by preparing a series of N-methylated {alpha}I epitope analogues and measuring their binding affinity and off-rate constants to DQ2. Additionally, we measured the binding of {alpha}I-gliadin peptide analogues in which norvaline, which contains a backbone amide hydrogen bond donor, was substituted for each proline. Our results demonstrate that hydrogen bonds at P4 and P2 positions are most important for binding, whereas the hydrogen bonds at P9 and P6 make smaller contributions to the overall binding affinity. There is no evidence for a hydrogen bond between DQ2 and the P1 amide nitrogen in peptides without proline at this position. This is a unique feature of DQ2 and is likely a key parameter for preferential binding of proline-rich gluten peptides and development of celiac disease.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Celiac disease is a complex genetic disorder of the small intestine caused by an inflammatory response to dietary wheat gluten (gliadins and glutenins) and related proteins from rye and barley (1). It is a prevalent disease affecting about 1 in 100 Caucasians (2). The lesion is characterized by villous atrophy, crypt cell hyperplasia, and infiltration of inflammatory cells. The villous atrophy may lead to malabsorption, but various extraintestinal symptoms often dominate the clinical picture (3). There is a strong HLA association in this disorder, and the primary susceptibility is mediated by HLA-DQ2 in the great majority of patients (4). Gluten-reactive T cells that recognize gluten peptides exclusively in the context of DQ2 are found in the gut lesions of DQ2-positive patients (5). This preferential antigen presentation explains the strong HLA association (6). There are several gluten T-cell epitopes that are recognized by intestinal T cells, and these epitopes are particularly rich in proline and glutamine residues (7–9).1 Most T-cell epitopes harbor glutamate residues that have been deamidated from glutamine residues by the action of tissue transglutaminase (11, 12). Proline residues confer resistance to proteolysis by digestive enzymes (13) and influence the selective targeting of glutamine residues by tissue transglutaminase (14, 15).

Binding of peptides to major histocompatibility complex (MHC) 2 class II molecules involves interaction of peptide side chains at the P1, P4, P6, P7, and P9 positions to pockets of the HLA binding site as well as hydrogen bonding between conserved residues of the HLA molecule and main chain carbonyl oxygen (C=O) and amide nitrogen (N-H) groups of the peptide (16). Crystallographic studies demonstrate that the pattern of hydrogen bonding to main chain atoms is similar between MHC alleles, and the involved MHC residues are often conserved across MHC alleles. The hydrogen bonding to the structurally conserved backbone explains why a single MHC class II molecule can accommodate a large number of disparate peptide sequences.

The x-ray crystal structure of DQ2 complexed with the deamidated T-cell epitope {alpha}I-gliadin QLQPFPQPELPY provided the molecular basis for the superior ability of DQ2 to bind the biased repertoire of proline-rich gluten peptides that have survived gastrointestinal digestion and been deamidated by tissue transglutaminase (17). Despite the inability of proline to act as a hydrogen bond donor, the {alpha}I-gliadin peptide binds to DQ2 with an extensive hydrogen bonding network. The multiple proline residues in gluten-derived epitopes impose a selectivity filter for MHC binding that is unrelated to side chain interactions because only a limited number of registers will maintain the essential main chain interactions. In the few permissible registers, DQ2 can effectively bind deamidated gluten peptides via its interaction with negatively charged anchor residues at P4, P6, or P7.

Notwithstanding a common backbone hydrogen bonding pattern, there is some variation among different MHC alleles (16). Some of the hydrogen bonds are mediated via polymorphic MHC residues (such as tyrosine {beta}30 and the P7 amide in DR3/CLIP (18), I-Ad/Ova (19), I-Ak/Hel (20), and lysine {beta}71 and the P5 carbonyl in DQ2/gliadin-{alpha}I (17)), whereas some peptide-MHC complexes appear not to utilize hydrogen bonds to conserved MHC residues (such as tryptophan {beta}61 and the P8 carbonyl in I-Ak/Hel (20)). Given this variation, MHC class II molecules may differ in their ability to bind proline-containing peptides with their atypical backbone. DQ2 may have unique characteristics in this regard.



View larger version (15K):
[in this window]
[in a new window]
  		FIG. 1.
Schematic representation of the hydrogen bond network between HLA-DQ2 and the backbone of the {alpha}I-gliadin peptide. The hydrogen bonds are indicated by dashed lines. The four hydrogen bonds between DQ2 and amide groups of the peptide main chain are marked with gray boxes. The figure is based on Ref. 17.

 
The significance of main chain hydrogen bond interactions in the presentation of proline-rich gluten epitopes by MHC is poorly understood. Detailed knowledge about these interactions is needed to better understand the HLA association in celiac disease. To establish the relative importance of hydrogen bonding between DQ2 and the amide nitrogen atoms of the {alpha}I-gliadin epitope (Fig. 1), we prepared and analyzed a series of N-methylated peptides. Together with depsipeptides, N-methylated peptides are invaluable reagents for evaluating the role of backbone hydrogen bonds in protein-ligand interactions (21), and they have therefore also been exploited in MHC structure-function studies (22–24). In addition, we prepared and analyzed several norvaline-containing analogues to assess the potential for amide nitrogen-mediated hydrogen bonding in positions occupied by proline residues in the DQ2-{alpha}I-gliadin complex. Our results highlight a critical role for hydrogen bonding at P2 and P4 positions in a proline-rich DQ2 epitope.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Peptide Synthesis—N-Methylated peptides used in this study were synthesized using Boc/HBTU chemistry starting from N-{alpha}-t-Boc-L-aminoacyl-phenylacetamidomethyl resin. For N-methylated positions, Boc-protected N-methylated amino acids were used, with HATU as the activation reagent. Triple coupling with prolonged coupling time (>1h) pushed the reactions closer to completion. Following cleavage of the peptidyl resin in trifluoroacetic acid/trifluoromethanesulfonic acid/thioanisole (10:1:1, v/v/v) for 4 h, the crude peptides were precipitated in cold ether and dissolved in 1:1 (v/v) acetonitrile/water. The peptides were purified by reverse-phase high pressure liquid chromatography on a semi-preparative C18 column using a water-acetonitrile gradient in 0.1% (v/v) trifluoroacetic acid. The molecular masses of the peptides were confirmed by liquid chromatography-electrospray mass spectrometry. The exact sequences of all the N-methylated peptides were confirmed by the fragmentation pattern using tandem mass spectrometry analysis. The peptides were lyophilized and stored at –20 °C before use.

Competitive HLA-DQ2-Peptide Binding Assay—Detergent-solubilized HLA-DQ2 (A1*0501, B*0201) molecules were purified from Epstein-Barr virus-transformed B lymphoblastoid cell lines as previously described (25). The indicator peptide (KPLLIIAEDVEGEY; Mycobacterium bovis 65-kDa Hsp 243–255Y) was 125I-labeled by the chloramine-T method (26). The labeled indicator peptide (30,000 cpm; 1–5 nM) and various concentrations of unlabeled peptides were incubated with 100–300 nM DQ2 overnight at 37 °C in the presence of a mixture of protease inhibitors (25). Complexes of peptide and DQ2 were separated from unbound peptides by spin column chromatography technique as described previously (27). Radioactivity was counted, and the concentrations of the competing peptides required to give 50% inhibition of the binding of the indicator peptide (IC50) were calculated. The IC50 values were determined by four consecutive titration experiments; first we did a 10-fold titration, then a 4-fold titration, and finally, two 3-fold titration experiments around the estimated IC50 values. The consistency of the results was excellent, and the results from one of the 3-fold titration experiments are presented.

Dissociation Experiments—Preformed complexes were prepared by incubating radiolabeled peptide with purified HLA-DQ2 overnight at 37 °C. Conditions were identical to those employed in the binding assay, except that the concentration of radiolabeled peptide was 10-fold higher. The complexes were isolated by spin columns and then incubated at pH 5.2 in the presence of protease inhibitors (as described in the peptide binding assay) at 37 °C. Aliquots were removed at various time points and separated on spin columns. The dissociation kinetics were fit into the one-phase exponential decay function (Y = As x exp(–ksx)) or the two-phase exponential decay function (Y = Af x exp(–kfx) + As x exp(–ksx)) using GraphPad Prism (Version 3.02).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Binding of N-Methylated Peptides—The importance of hydrogen bonds mediated by the peptide main chain amide groups was investigated by testing the binding of a series of N-methylated variants of the peptides LQPFPEPELPY and AAIAAVKEEAF. By N-methylation, the N-H groups of the peptide backbone were converted to N-CH3 groups that are unable to engage in hydrogen bonding. The LQPFPEPELPY peptide was used instead of the LQPFPQPELPY peptide because it has a 4-fold higher affinity to DQ2. IC50 values of the two peptide series were measured using a competitive binding assay with a radiolabeled indicator peptide. The experimentally determined IC50 values of these peptides are given in Figs. 2 and 3. N-Methylation at position P2 and P4 in the {alpha}I-gliadin peptide resulted in substantially reduced binding affinity (35.6- and 23.3-fold, respectively), indicating that hydrogen bond interactions at these positions contribute significantly to peptide binding. N-Methylation at the P9 position also resulted in an 8.0-fold reduction in binding affinity. In contrast, the high affinity, proline-free AAIAAVKEEAF peptide showed decreased affinity when N-methylated at positions P4 and P9 (10.5- and 5.1-fold, respectively), but not at P2. Of note, the discriminatory effect of N-methylation was more pronounced for the LQPFPEPELPY peptide than the AAIAAVKEEAF peptide.



View larger version (9K):
[in this window]
[in a new window]
  		FIG. 2.
IC50 values of N-methylated analogues of the modified {alpha}I-gliadin peptide LQPFPEPELPY. IC50 is the peptide concentration required to give 50% inhibition of the indicator peptide KPLLIIAEDVEGEY. The O in the amino acid sequence denotes N-methylated amino acid.

 



View larger version (11K):
[in this window]
[in a new window]
  		FIG. 3.
IC50 values for the N-methylated high affinity binder peptide AAIAAVKEEAF. The O in the amino acid sequence denotes N-methylated amino acid.

 
Dissociation of N-Methylated Peptides—The importance of hydrogen bonding was further addressed by dissociation experiments. For the LQPFPEPELPY analogue series, we were unable to form significant amounts of complexes with peptides N-methylated at the P2 and P4 positions, presumably due to their low affinity for DQ2. The dissociation experiment results are given in Fig. 4 and Table I. Peptides that were N-methylated at either position P6 or P9 showed faster dissociation compared with the unmethylated peptide, whereas the peptide N-methylated at position P7 had a dissociation rate similar to that of the unmethylated peptide. Consistent with this result, the DQ2-{alpha}I-gliadin crystal structure revealed no hydrogen bonding at the P7 position. The YAAIAAVKEEAF peptide, containing a tyrosine at the N terminus for labeling purposes, was synthesized for additional dissociation experiments. More than 60% of the peptide-DQ2 complexes remained intact after 30 days (data not shown). The slow dissociation of this peptide from DQ2 prevented us from proceeding with the testing of N-methylated variants.


View this table:
[in this window]
[in a new window]
  		TABLE I
Dissociation kinetic parameters of N-methylated {alpha}I-gliadin peptide

 
Binding of Norvaline-substituted Peptides—To probe for the potential for hydrogen bonding at positions occupied by proline residues in the {alpha}I-gliadin epitope, a series of peptides containing norvaline in place of proline was tested for binding to DQ2 in a competitive binding assay. Norvaline is an acyclic amino acid that is isosteric to proline and can therefore participate in backbone hydrogen bonding. The IC50 values for these peptides are shown in Fig. 5. In contrast to the experiments summarized in Fig. 2, the native (weaker-binding) {alpha}I-gliadin epitope was used here to maximize the chances of detecting energetically favorable hydrogen bonds that are masked by proline residues. The analogue with a norvaline substitution at position P1 bound to DQ2 with a higher IC50 value, contrary to what is expected when an additional hydrogen bond is present in the binding of the peptide. All other norvaline-substituted peptides (at positions P3, P5, and P8) had moderately (1.5–5.4-fold) lower IC50 values than the unsubstituted peptide.



View larger version (13K):
[in this window]
[in a new window]
  		FIG. 4.
Dissociation of N-methylated analogues of the modified {alpha}I-gliadin peptide LQPFPEPELPY from DQ2. Remaining complexes of DQ2 and the peptides P1563 LQPFPEPOLPY ({blacksquare}), P1564 LQPFPEPEOPY ({blacktriangledown}), P1565 LQPFPEPELPO ({diamondsuit}), and P1550 LQPFPEPELPY (•) are plotted against time. The O in the amino acid sequences denotes N-methylated amino acid.

 
Dissociation of Norvaline-substituted Peptides—Peptide dissociation experiments were performed to further characterize the hydrogen bonds in the norvaline-substituted peptides. The results are shown in Fig. 6 and Table II. DQ2 complexes with peptides containing a norvaline substitution at P1 or P3 had a half-life comparable to that of the unsubstituted peptide, whereas the P5 substitution resulted in a considerably increased half-life, primarily due to virtual abolition of the fast phase of the dissociation curve.


View this table:
[in this window]
[in a new window]
  		TABLE II
Dissociation kinetic parameters of norvaline-substituted {alpha}I-gliadin peptide

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
The abundance of proline residues in gluten epitopes is a hallmark of celiac disease. This, in turn, has led to an increased appreciation for the possibility that the mechanistic consequences of certain proline-rich motifs may be a key to understanding celiac disease pathogenesis. This enigmatic relationship between proline and celiac disease is perhaps most vividly illustrated by the affinity of gluten epitopes for HLA-DQ2. Although the importance of backbone hydrogen bonding in MHC-ligand interactions is widely appreciated, T-cell epitopes from gluten can have as many as four proline residues, none of which are able to act as backbone hydrogen bond donors. To understand the molecular logic for high affinity binding of such epitopes, we have systematically investigated the effect of disrupting hydrogen bond interactions by N-methylation of nonproline residues and proline-to-norvaline substitutions in the celiac disease-relevant gluten T-cell epitope, {alpha}I-gliadin. Our results indicate that backbone hydrogen bonds at P2 and P4 contribute significantly to the overall binding energy, whereas those at P6 and P9 are less important. Moreover, we found no evidence for a hydrogen bond between DQ2 and the P1 amide nitrogen in a peptide analogue that should be capable of establishing this bond. This property differentiates DQ2 from other human MHC class II molecules and is therefore likely a key parameter for explaining the preferential binding of prolinerich gluten peptides to DQ2.



View larger version (7K):
[in this window]
[in a new window]
  		FIG. 5.
IC50 values of norvaline substituted {alpha}I-gliadin peptide. IC50 is the peptide concentration required to give 50% inhibition of the indicator peptide KPLLIIAEDVEGEY. The Z in the amino acid sequence denotes norvaline.

 



View larger version (13K):
[in this window]
[in a new window]
  		FIG. 6.
Dissociation of norvaline substituted {alpha}I-gliadin peptide from DQ2. Remaining complexes of DQ2 and the peptides P1546 LQZFPQPELPY ({blacksquare}), P1547 LQPFZQPELPY ({blacktriangledown}), P1548 LQPFPQZELPY ({diamondsuit}), and P1281 LQPFPQPELPY (•) are plotted against time. The Z in the amino acid sequences denotes norvaline.

 
Several previous studies have addressed the importance of hydrogen bonding to the peptide main chain for binding to MHC class II molecules. These include mutational study of the MHC class II molecules (28–31) as well as binding assay of peptide analogues containing reduced peptide bonds or N-methylated amino acids (22, 24, 32, 33). Gliadin T-cell epitopes presented by DQ2 molecules are particularly rich in proline residues. In this study, we examined the relative contribution of individual backbone hydrogen bond interactions by comparing the binding and dissociation of backbone N-methylated analogues in the context of HLA-DQ2. N-Methylation could affect peptide binding by interfering with the amide group hydrogen bond formation. It could also affect the free energy of binding as the result of introducing a hydrophobic methyl group or impose steric effects. The results must be interpreted with this in mind. The most prominent effect for peptide binding was observed for analogues N-methylated at the P2 and P4 positions. This is consistent with the crystal structure of the DQ2-{alpha}I-gliadin complex, which shows hydrogen bonds at these positions. The crystal structure also indicated hydrogen bonds mediated by the amide nitrogen at the P6 and P9 positions. The analogues with N-methylation at positions P6 and P9 displayed some reduced binding, and the off-rates of these analogues were clearly increased. Taken together, these results are compatible with the notion that the hydrogen bonds at the P6 and P9 positions are energetically less important than those at the P2 and P4 positions. The DQ2-{alpha}I-gliadin structure gave no indication of a hydrogen bond to the P7 amide. The analogue with N-methylation at position P7 had a slightly higher IC50 compared with the unmodified peptide, whereas the off-rate was unaltered. In the crystal structure, the amide of P7 residue points directly toward DQ2. Therefore, methylation at the P7 position may cause a steric clash, thereby impairing ligand binding. Whereas results from the N-methylated analogues of the {alpha}I-gliadin peptide showed clear discrimination, there was little difference in IC50 values for N-methylated analogues of the AAIAAVKEEAF peptide, a peptide designed to bind well to DQ2 that lacks any proline residues. A reason for this could be the high binding affinity and strong interaction of this peptide at several positions in the DQ2 binding site.

Strategic positioning of proline residues that maintains the backbone hydrogen bond network provides an explanation for the observation that proline residues are never found at the P2, P4, or P9 positions in gluten T-cell epitopes bound to DQ2. The localization of proline at the P6 position in some DQ2-restricted gluten T-cell epitopes is, however, in conflict with this scheme. Similarly, one could expect that N-methylation at the P6 position would have less effect than N-methylation at the P9 position. The IC50 values for the analogues with N-methylation at P6 and P9 are virtually the same, whereas the off-rate is higher for the analogue with N-methylation at P6. A possible explanation for this is that the side chain of proline is a favorable anchor for the P6 pocket, but not for the P9 pocket (34, 35), and that in gluten T-cell epitopes, the effect of the side chain interactions for proline will dominate over the lack of main chain interactions at the P6, but not the P9, position.

In the DQ2-{alpha}I-gliadin complex crystal structure, there is a proline residue positioned at P1, and hence there is no hydrogen bond to the amide nitrogen at this position. All currently available crystal structures of MHC class II molecules (DR1, DR2, DR3, DR4, I-Ek, DQ8, DQ6, I-Ak, I-Au, I-Ab, I-Ad, and I-Ag7) (18–20, 36–45) are complexes with peptides that do not have proline at P1, and in all cases there is a hydrogen bond between the P1 amide nitrogen and the backbone carbonyl group of the {alpha}53 residue. Interestingly, DQ2 has a deletion of the {alpha}53 residue, and it is conceivable that DQ2 is unable to establish a hydrogen bond to the P1 amide nitrogen (17). Previous functional assays suggest that the P1 hydrogen bond is critical for binding of peptides to DR molecules. In binding analysis of DR1 and DR4 (0401, a subtype of DR4) for N-methylated peptide series, the weakest binding was found for analogues with N-methylation at the P1 position (24, 32). Similarly, off-rate analysis of DR1-peptide complexes showed the highest off-rate for the peptide with N-methylation at P1 both for DM-catalyzed and non-DM-catalyzed reactions (33). For I-Ed, similar binding analysis did not reveal any clear effects for N-methylated analogues representing the P1–P9 positions (22), although I-Ed does not have a deletion at {alpha}53. To probe the possibility of hydrogen bond formation between the P1 amide and DQ2, we tested an analogue of the {alpha}I-gliadin peptide containing a norvaline substitution at P1. Norvaline and proline have the same number of carbon atoms in their side chains, but in contrast to proline, the side chain of norvaline does not have a cyclic structure. Compared with the unmodified {alpha}I-gliadin peptide, the P1 norvaline analogue bound with a higher IC50 value and had the same off-rate. This suggests that DQ2 binds peptides without establishing a hydrogen bond to the P1 amide. The majority of the gluten T-cell epitopes characterized so far (10),1 including the {alpha}I-gliadin peptide, bind to DQ2 with proline residues positioned at the P1 position. Presumably, proline may be accommodated at this position with no penalty, despite the lack of hydrogen bond to the peptide backbone.

In a study assessing the relative importance of main chain hydrogen bonds toward HLA-DM action in HLA-DR1, Stratikos et al. (33) observed that disrupting hydrogen bonds involving DR{alpha} residues 51–53, and in particular the hydrogen bond between the P1 amide and the carbonyl of {alpha}53, led to heightened HLA-DM catalytic efficacy. The authors suggest that these hydrogen bonds are disrupted in the MHC conformation recognized by HLA-DM, thereby allowing a conformational shift in the short extended strand formed by the {alpha}51–53 region and facilitating peptide exchange. Our observation that DQ2 binds peptides without establishing the hydrogen bond to the P1 amide suggests that the interaction between DQ2 and HLA-DM may differ qualitatively from that of many other MHC class II molecules. In this respect it is interesting that invariant chain (i.e. CLIP) peptides are remarkably abundant among the endogenous peptides eluted from DQ2 molecules of B-cell lines (34, 35).

Higher affinity and slow dissociation of the {alpha}I-gliadin peptide substituted with norvaline at P5 is compatible with the notion that DQ2 has the potential to establish a hydrogen bond to the peptide P5 amide. Several MHC class II molecules (I-Ad, I-Ak, I-Au, I-Ab, and I-Ag7) (19, 20, 42, 43, 45) do have a hydrogen bond between glutamate {beta}74 and the P5 amide. The side chain of alanine {beta}74 in DQ2 is, however, not a hydrogen bond acceptor. The entropic effect imposed by the proline residue can be another factor explaining our observations for the P5 substitution. Higher backbone flexibility resulting from norvaline substitution could lead to better docking of the side chains in the neighboring pockets.

For some N-methylated peptide analogues, the binding was impaired so severely that it was impossible to generate a sufficient amount of peptide-MHC complexes to determine dissociation rates. However, for many of the analogues, both IC50 values and off-rate constants were established. With few exceptions, one being the {alpha}I-gliadin analogue N-methylated at the P7 position, the results of the two binding parameters paralleled each other. This underscores the importance of the off-rate component in the IC50 value. A steric effect of the methyl group at P7 amide for peptide docking could explain the dissonant observation at the P7 position.

Blocking of peptide presentation by DQ2 is an attractive approach for a new treatment of celiac disease because DQ2 (or DQ8) is a necessary but insufficient genetic component for disease development. Such a blocker can most easily be administered locally at the intestinal surface parallel to gluten antigen ingestion. In this regard, celiac disease differs radically from other HLA-associated diseases for which this type of intervention also has been suggested. Effective inhibition of antigen presentation will likely require a slow off-rate of the blocking compound. A blocking compound can be designed as a peptidomimetic, and the ability to achieve slow off-rate will require the peptidomimetic compound to successfully establish hydrogen bonds to amide nitrogen at the P2 and P4 positions. A blocking compound will also have to be designed such that the T-cell receptor is prevented from making a productive contact to the blocker-DQ2 complex, and the blockers should also be proteolytically stable. How this should be obtained will be the focus of additional studies.


   FOOTNOTES
 
* This work was supported by grants from the Research Council of Norway and by National Institutes of Health Grants DK65965 and DK63158. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§ To whom correspondence should be addressed. Tel.: 47-23073815; Fax: 47-23073510; E-mail: elin.bergseng{at}medisin.uio.no.

1 S. W. Qiao, E. Bergseng, Ø. Molberg, G. Jung, B. Fleckenstein, and L. M. Sollid, submitted for publication. Back

2 The abbreviations used are: MHC, major histocompatibility complex; HATU, O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; Boc, t-butoxycarbonyl. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Sollid, L. M. (2002) Nat. Rev. Immunol. 2, 647–655[CrossRef][Medline] [Order article via Infotrieve]
  2. Maki, M., Mustalahti, K., Kokkonen, J., Kulmala, P., Haapalahti, M., Karttunen, T., Ilonen, J., Laurila, K., Dahlbom, I., Hansson, T., Hopfl, P., and Knip, M. (2003) N. Engl. J. Med. 348, 2517–2524[Abstract/Free Full Text]
  3. Green, P. H. R., and Jabri, B. (2003) Lancet 362, 383–391[CrossRef][Medline] [Order article via Infotrieve]
  4. Sollid, L. M., and Thorsby, E. (1993) Gastroenterology 105, 910–922[Medline] [Order article via Infotrieve]
  5. Lundin, K. E., Scott, H., Hansen, T., Paulsen, G., Halstensen, T. S., Fausa, O., Thorsby, E., and Sollid, L. M. (1993) J. Exp. Med. 178, 187–196[Abstract/Free Full Text]
  6. Sollid, L. M. (2000) Annu. Rev. Immunol. 18, 53–81[CrossRef][Medline] [Order article via Infotrieve]
  7. Arentz-Hansen, H., Korner, R., Molberg, Ø., Quarsten, H., Vader, W., Kooy, Y. M., Lundin, K. E., Koning, F., Roepstorff, P., Sollid, L. M., and McAdam, S. N. (2000) J. Exp. Med. 191, 603–612[Abstract/Free Full Text]
  8. Arentz-Hansen, H., McAdam, S. N., Molberg, Ø., Fleckenstein, B., Lundin, K. E., Jorgensen, T. J., Jung, G., Roepstorff, P., and Sollid, L. M. (2002) Gastroenterology 123, 803–809[CrossRef][Medline] [Order article via Infotrieve]
  9. Vader, W., Kooy, Y., van Veelen, P., de Ru, A., Harris, D., Benckhuijsen, W., Pena, S., Mearin, L., Drijfhout, J. W., and Koning, F. (2002) Gastroenterology 122, 1729–1737[CrossRef][Medline] [Order article via Infotrieve]
  10. Vader, W., Stepniak, D., Kooy, Y., Mearin, L., Thompson, A., van Rood, J. J., Spaenij, L., and Koning, F. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 12390–12395[Abstract/Free Full Text]
  11. Molberg, Ø., McAdam, S. N., Korner, R., Quarsten, H., Kristiansen, C., Madsen, L., Fugger, L., Scott, H., Noren, O., Roepstorff, P., Lundin, K. E., Sjostrom, H., and Sollid, L. M. (1998) Nat. Med. 4, 713–717[CrossRef][Medline] [Order article via Infotrieve]
  12. van de Wal, Y., Kooy, Y., van Veelen, P., Pena, S., Mearin, L., Papadopoulos, G., and Koning, F. (1998) J. Immunol. 161, 1585–1588[Abstract/Free Full Text]
  13. Hausch, F., Shan, L., Santiago, N. A., Gray, G. M., and Khosla, C. (2002) Am. J. Physiol. Gastrointest. Liver Physiol. 283, G996–G1003[Abstract/Free Full Text]
  14. Vader, L. W., de Ru, A., van der Wal, Y., Kooy, Y. M., Benckhuijsen, W., Mearin, M. L., Drijfhout, J. W., van Veelen, P., and Koning, F. (2002) J. Exp. Med. 195, 643–649[Abstract/Free Full Text]
  15. Fleckenstein, B., Molberg, Ø., Qiao, S. W., Schmid, D. G., von der Mulbe, F., Elgstoen, K., Jung, G., and Sollid, L. M. (2002) J. Biol. Chem. 277, 34109–34116[Abstract/Free Full Text]
  16. Nelson, C. A., and Fremont, D. H. (1999) Rev. Immunogenet. 1, 47–59[Medline] [Order article via Infotrieve]
  17. Kim, C. Y., Quarsten, H., Bergseng, E., Khosla, C., and Sollid, L. M. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 4175–4179[Abstract/Free Full Text]
  18. Ghosh, P., Amaya, M., Mellins, E., and Wiley, D. C. (1995) Nature 378, 457–462[CrossRef][Medline] [Order article via Infotrieve]
  19. Scott, C. A., Peterson, P. A., Teyton, L., and Wilson, I. A. (1998) Immunity 8, 319–329[CrossRef][Medline] [Order article via Infotrieve]
  20. Fremont, D. H., Monnaie, D., Nelson, C. A., Hendrickson, W. A., and Unanue, E. R. (1998) Immunity 8, 305–317[CrossRef][Medline] [Order article via Infotrieve]
  21. Bramson, H. N., Thomas, N. E., and Kaiser, E. T. (1985) J. Biol. Chem. 260, 5452–5457
  22. Cotton, J., Herve, M., Pouvelle, S., Maillere, B., and Menez, A. (1998) Int. Immunol. 10, 159–166[Abstract/Free Full Text]
  23. Zavala-Ruiz, Z., Sundberg, E. J., Stone, J. D., De Oliveira, D. B., Chan, I. C., Svendsen, J., Mariuzza, R. A., and Stern, L. J. (2003) J. Biol. Chem. 278, 44904–44912[Abstract/Free Full Text]
  24. Falcioni, F., Ito, K., Vidovic, D., Belunis, C., Campbell, R., Berthel, S. J., Bolin, D. R., Gillespie, P. B., Huby, N., Olson, G. L., Sarabu, R., Guenot, J., Madison, V., Hammer, J., Sinigaglia, F., Steinmetz, M., and Nagy, Z. A. (1999) Nat. Biotechnol. 17, 562–567[CrossRef][Medline] [Order article via Infotrieve]
  25. Johansen, B. H., Buus, S., Vartdal, F., Viken, H., Eriksen, J. A., Thorsby, E., and Sollid, L. M. (1994) Int. Immunol. 6, 453–461[Abstract/Free Full Text]
  26. Greenwood, F. C., Hunter, W. M., and Glover, J. S. (1963) Biochem. J. 89, 114–123[Medline] [Order article via Infotrieve]
  27. Buus, S., Stryhn, A., Winther, K., Kirkby, N., and Pedersen, L. O. (1995) Biochim. Biophys. Acta 1243, 453–460[Medline] [Order article via Infotrieve]
  28. McFarland, B. J., Beeson, C., and Sant, A. J. (1999) J. Immunol. 163, 3567–3571[Abstract/Free Full Text]
  29. Arneson, L. S., Katz, J. F., Liu, M., and Sant, A. J. (2001) J. Immunol. 167, 6939–6946[Abstract/Free Full Text]
  30. McFarland, B. J., Katz, J. F., Beeson, C., and Sant, A. J. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 9231–9236[Abstract/Free Full Text]
  31. Sant, A. J., Beeson, C., McFarland, B., Cao, J., Ceman, S., Bryant, P. W., and Wu, S. H. (1999) Immunol. Rev. 172, 239–253[CrossRef][Medline] [Order article via Infotrieve]
  32. Hill, C. M., Liu, A., Marshall, K. W., Mayer, J., Jorgensen, B., Yuan, B., Cubbon, R. M., Nichols, E. A., Wicker, L. S., and Rothbard, J. B. (1994) J. Immunol. 152, 2890–2898[Abstract]
  33. Stratikos, E., Wiley, D. C., and Stern, L. J. (2004) J. Immunol. 172, 1109–1117[Abstract/Free Full Text]
  34. Vartdal, F., Johansen, B. H., Friede, T., Thorpe, C. J., Stevanovic, S., Eriksen, J. E., Sletten, K., Thorsby, E., Rammensee, H. G., and Sollid, L. M. (1996) Eur. J. Immunol. 26, 2764–2772[Medline] [Order article via Infotrieve]
  35. van de Wal, Y., Kooy, Y. M., Drijfhout, J. W., Amons, R., and Koning, F. (1996) Immunogenetics 44, 246–253[CrossRef][Medline] [Order article via Infotrieve]
  36. Stern, L. J., Brown, J. H., Jardetzky, T. S., Gorga, J. C., Urban, R. G., Strominger, J. L., and Wiley, D. C. (1994) Nature 368, 215–221[CrossRef][Medline] [Order article via Infotrieve]
  37. Smith, K. J., Pyrdol, J., Gauthier, L., Wiley, D. C., and Wucherpfennig, K. W. (1998) J. Exp. Med. 188, 1511–1520[Abstract/Free Full Text]
  38. Dessen, A., Lawrence, C. M., Cupo, S., Zaller, D. M., and Wiley, D. C. (1997) Immunity 7, 473–481[CrossRef][Medline] [Order article via Infotrieve]
  39. Fremont, D. H., Hendrickson, W. A., Marrack, P., and Kappler, J. (1996) Science 272, 1001–1004[Abstract]
  40. Lee, K. H., Wucherpfennig, K. W., and Wiley, D. C. (2001) Nat. Immunol. 2, 501–507[CrossRef][Medline] [Order article via Infotrieve]
  41. Siebold, C., Hansen, B. E., Wyer, J. R., Harlos, K., Esnouf, R. E., Svejgaard, A., Bell, J. I., Strominger, J. L., Jones, E. Y., and Fugger, L. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 1999–2004[Abstract/Free Full Text]
  42. He, X. L., Radu, C., Sidney, J., Sette, A., Ward, E. S., and Garcia, K. C. (2002) Immunity 17, 83–94[CrossRef][Medline] [Order article via Infotrieve]
  43. Liu, X. Q., Dai, S. D., Crawford, F., Fruge, R., Marrack, P., and Kappler, J. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 8820–8825[Abstract/Free Full Text]
  44. Zhu, Y. R., Rudensky, A. Y., Corper, A. L., Teyton, L., and Wilson, I. A. (2003) J. Mol. Biol. 326, 1157–1174[CrossRef][Medline] [Order article via Infotrieve]
  45. Latek, R. R., Suri, A., Petzold, S. J., Nelson, C. A., Kanagawa, O., Unanue, E. R., and Fremont, D. H. (2000) Immunity 12, 699–710[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/23/21791    most recent
M501558200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bergseng, E.
Right arrow Articles by Sollid, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bergseng, E.
Right arrow Articles by Sollid, L. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.